Latest News for: roa

Edit

WSFS Reports 1Q 2026 EPS of $1.64 and ROA of 1.61% Strong Year Over Year ...

Business Wire 24 Apr 2026
WILMINGTON, Del.--(BUSINESS WIRE)--WSFS Financial Corporation (Nasdaq ... Selected financial results and metrics are as follows.
Edit

ICC Pre-Trial Chamber I confirms all charges against Rodrigo Roa Duterte and commits him to trial (ICC - International Criminal Court)

Public Technologies 23 Apr 2026
... by the Prosecutor against Rodrigo Roa Duterte and committed him to trial before a Trial Chamber ... Public redacted version of 'Decision on the confirmation of charges against Mr Rodrigo Roa Duterte'.
Edit

WSFS REPORTS 1Q 2026 EPS OF $1.64 AND ROA OF 1.61% STRONG YEAR OVER YEAR DEPOSIT AND FEE GROWTH BOARD APPROVED 18% DIVIDEND INCREASE, NEW 15% BUYBACK AUTHORIZATION (Form 8-K) (WSFS Financial Corporation)

Public Technologies 23 Apr 2026
) WSFS REPORTS 1Q 2026 EPS OF $1.64 AND ROA OF 1.61% ... Return on average assets (ROA) (a) 1.61 % 1.33 % 1.29 % ... •Core EPS of $1.68 increased 17% and core ROA(2) of 1.65% increased 23bps compared to 4Q 2025 ... ROA 2.38 % 2.11 % 1.21 %.
Edit

THE BANCORP REPORTS 1Q 2026 EPS OF $1.41, ROA OF 2.57%, AND ROE OF 35.1% DRIVEN BY STRONG GROWTH IN LOANS, DEPOSITS AND PAYMENTS VOLUME, AND SUPPORTED BY CONTINUED IMPROVEMENT IN CREDIT PERFORMANCE (Form 8-K) (The Bancorp Inc)

Public Technologies 23 Apr 2026
). THE BANCORP REPORTS 1Q 2026 EPS OF $1.41, ROA OF 2.57%, AND ROE OF 35.1%. DRIVEN BY STRONG GROWTH IN LOANS, DEPOSITS AND PAYMENTS VOLUME,. AND SUPPORTED BY CONTINUED IMPROVEMENT IN CREDIT PERFORMANCE ... _______ ... 1 ... (NASDAQ ... Unaudited) ... Volume. ... 2 ... 3 ... _______.
Edit

Amyotrophic Lateral Sclerosis Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight ...

GetNews 20 Apr 2026
“" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Amyotrophic Lateral Sclerosis Market ... Patent No ... Products have been categorized under various ROAs, such as.
Edit

NZEI Te Riu Roa Demands: Restore Te Tiriti Obligations And Halt Curriculum Rollout

Scoop 15 Apr 2026
The group is advocating for an education system that is equitable, honours its promises to Māori, and ensures every ākonga sees themselves in their learning ....
Edit

Peripheral Artery Disease Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by ...

GetNews 15 Apr 2026
“" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Peripheral Artery Disease Market ... REX-001 ... ACP-01 ... Products have been categorized under various ROAs, such as.
Edit

Pin Ads Establishes Itself as Europe’s Leading Pinterest Advertising Agency, Delivering Superior ROAS for Brands ...

GetNews 15 Apr 2026
The agency is authorised to manage budgets running into the tens of millions of euros annually, with optimisation frameworks proven to sustain strong ROAS even as spend scales ... above-benchmark ROAS.
Edit

HOMB’s Top-Tier Performance Continues into 2026 with First Quarter Earnings of $118.2 Million, EPS of $0.60 and ROA of 2.09% (Form 8-K) (Home BancShares Inc)

Public Technologies 15 Apr 2026
Earnings of $118.2 Million, EPS of $0.60 and ROA of 2.09% ... ROA 2.09% ... ROA, as adjusted (non-GAAP)(1) ... The Company delivered strong and improving return on average assets (ROA) during the first quarter of 2026, with an ROA of approximately 2.09%.
Edit

HOMB’s Top-Tier Performance Continues into 2026 with First Quarter Earnings of $118.2 Million, EPS of $0.60 and ROA of 2.09% (Home BancShares Inc)

Public Technologies 15 Apr 2026
ROA 2.09% 2.06% 2.17% 2.08% 2.07%. ROA, as adjusted (non-GAAP)(1) 2.09% 2.05% 2.10% 2.02% 2.01% ... The Company delivered strong and improving return on average assets (ROA) during the first quarter of 2026, with an ROA of approximately 2.09% ... QTD ROA.
Edit

Night Vision Disturbances Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by ...

GetNews 10 Apr 2026
The Night Vision Disturbances Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase ... Products have been categorized under various ROAs, such as ... 1.
Edit

Hypertrophic Cardiomyopathy Pipeline 2026: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved ...

GetNews 09 Apr 2026
“" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hypertrophic Cardiomyopathy Market ... (Nasdaq ... Products have been categorized under various ROAs, such as. Oral.
×